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OBJECTIVE—Peroxisome proliferator–activated receptor (PPAR)-
a/g dual agonists have been developed to alleviate metabolic disor-
ders. However, several PPARa/g dual agonists are accompanied
with unwanted side effects, including body weight gain, edema,
and tissue failure. This study investigated the effects of a novel
PPARa/g dual agonist, CG301269, on metabolic disorders both in
vitro and in vivo.
RESEARCH DESIGN AND METHODS—Function of CG301269
as a PPARa/g dual agonist was assessed in vitro by luciferase
reporter assay, mammalian one-hybrid assay, and analyses of
PPAR target genes. In vitro proﬁles on fatty acid oxidation and
inﬂammatory responses were acquired by fatty acid oxidation
assay and quantitative (q)RT-PCR of proinﬂammatory genes. In
vivo effect of CG301269 was examined in db/db mice. Total body
weight and various tissue weights were measured, and hepatic
lipid proﬁles were analyzed. Systemic glucose and insulin toler-
ance were measured, and the in vivo effect of CG301269 on
metabolic genes and proinﬂammatory genes was examined by
qRT-PCR.
RESULTS—CG301269 selectively stimulated the transcriptional
activities of PPARa and PPARg. CG301269 enhanced fatty acid
oxidation in vitro and ameliorated insulin resistance and hyper-
lipidemia in vivo. In db/db mice, CG301269 reduced inﬂammatory
responses and fatty liver, without body weight gain.
CONCLUSIONS—We demonstrate that CG301269 exhibits ben-
eﬁcial effects on glucose and lipid metabolism by simultaneous
activation of both PPARa and PPARg. Our data suggest that
CG301269 would be a potential lead compound against obesity
and related metabolic disorders. Diabetes 60:496–506, 2011
E
nergy homeostasis is regulated by metabolic
organs such as adipose tissue, liver, and muscle.
Excess energy produced by surplus nutrient in-
take or reduced energy expenditure, or both, is
mostly stored in the form of triglyceride (TG) in adipose
tissue (1). When adipose tissue fails to accommodate lipid
storage, excess energy is accumulated in other peripheral
tissues, including liver and skeletal muscle (2). Because
the increase of free fatty acids (FFAs) produced by TG
breakdown from peripheral tissues provokes insulin re-
sistance through diverse signaling pathways, including c-Jun
NH2-terminal kinase and protein kinase C (3,4), abnormal
lipid metabolism is closely associated with many meta-
bolic disorders, including obesity, insulin resistance, type 2
diabetes, hyperglycemia, hyperlipidemia, hypercholesterol-
emia, fatty liver, atherosclerosis, and cardiovascular dis-
eases (1). Therefore, numerous chemicals and therapeutic
agents targeting lipid metabolism have been developed to
treat lipid dysregulation and its related complications.
Peroxisome proliferator–activated receptors (PPARs),
members of the nuclear hormone receptors, are important
regulators of lipid metabolism. The PPAR family consists
of three isoforms, PPARa, PPARb/d, and PPARg (5).
Emerging evidence indicates that activation of PPARa or
PPARb/d would stimulate lipid consumption by enhancing
the expression of fatty acid oxidation genes, resulting in
amelioration of hyperlipidemia (6,7). PPARg, however,
controls lipid mobilization into adipocytes by promoting
adipogenesis and inducing the expression of lipid trans-
port genes such as adipocyte fatty acid binding protein
(aP2) and CD36, thereby reducing lipotoxicity (5,8).
By controlling lipid metabolism through distinct mech-
anisms, PPAR agonists have been widely used to rescue
lipid dysregulation and related metabolic disorders (9,10).
Thiazolidinedione, a synthetic PPARg ligand, greatly im-
proves insulin action, hyperglycemia, and lipotoxicity. How-
ever, several concerns such as body weight gain associated
with excess increase of fat mass arise in overt type 2 diabetic
patients (11). In contrast, ﬁbrate, a selective agonist for
PPARa, relieves lipid dysregulation greatly and insulin re-
sistance mildly by the induction of lipid catabolism in
hyperlipidemic patients, with a minor reduction of body
weight (6,12).
Because some ﬁbrates also have several side effects,
such as hepatotoxicity and gallstone formation (13–15), it
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ORIGINAL ARTICLEhas been proposed that more desirable effects with few
side effects (e.g., extra body weight gain and hepatotox-
icity) would be achieved by simultaneous activation of
PPARa and PPARg in a single chemical compound. In fact,
numerous PPARa/g dual agonists have been identiﬁed and
tested in obese and insulin-resistant individuals (16–18).
However, most of the current PPARa/g dual agonists that
have been developed have shown unexpected side effects
such as stroke and heart failure as well as body weight
gain (19–22). Therefore, the development of novel PPARa/g
dual agonists with little adverse effects is urgently needed.
In the current study, we characterized a novel PPARa/g
dual agonist, CG301269, which exhibits potent agonist
activity more toward PPARa rather than to PPARg.
CG301269 selectively stimulated the activities of PPARa
and PPARg. Biochemical and computational analyses
revealed that CG301269 is able to directly activate PPARa
and PPARg. In various cultured cell lines, CG301269 en-
hanced fatty acid oxidation while it suppressed proin-
ﬂammatory gene expression. Furthermore, in obese and
diabetic db/db mice, CG301269 improved the abnormalities
of lipid metabolism and insulin resistance without the
previously reported side effects of PPARa or PPARg single
agonists such as body weight gain, fatty liver, hepato-
megaly, and hepatotoxicity. Collectively, these data sug-
gest that CG301269 would be a potential therapeutic agent
for obesity and lipid dysregulation.
RESEARCH DESIGN AND METHODS
Materials. CG301269 was designed by Crystal Genomics (Seoul, Korea) and
synthesized by Korea Research Institute of Chemical Technology (Daejeon,
Korea). Rosiglitazone and WY14643 were purchased from Cayman Chemicals
(Ann Arbor, MI). Oil-red O, tumor necrosis factor a (TNFa), and lipopoly-
saccharide (LPS) were purchased from Sigma (St. Louis, MO). GW501516 was
provided by Dr. J.B. Seo.
Cell culture. Human embryonic kidney (HEK) 293 ﬁbroblasts, FAO rat hep-
atoma cells, C2C12 murine myocytes, 3T3-L1 murine adipocytes, and RAW
264.7 macrophages were purchased from the American Type Culture Collec-
tion (Manassas, VA). Media were supplemented with penicillin (100 units/mL)
and streptomycin (100 mg/mL). HEK 293 and 3T3-L1 cells were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% bovine
calf serum (both Hyclone, Logan, UT). FAO, C2C12, and RAW 264.7 cells were
grown in DMEM supplemented with 10% fetal bovine serum (Hyclone). Cells
were maintained at 37°C in a humidiﬁed atmosphere containing 5% CO2.C 2C12
cells were differentiated as described previously (23), and differentiated adi-
pocytes were prepared as described earlier (24).
Transient transfection and gene suppression. Transactivation reporter
assay in HEK 293 cells was performed as previously described (23). Brieﬂy,
cells were transiently transfected with murine PPARa or PPARg expression
vector, RXRa expression vector, b-galactosidase (b-gal) expression vector,
and DR-1 luciferase reporter vector. At 6 h after transfection, the transfection
mixture was replaced with fresh medium containing the appropriate agonist.
Luciferase assays were performed after 24 h. Mammalian one-hybrid assay
was performed by use of UAS-luciferase reporter vector and GAL4-PPARa
ligand-binding domain (LBD) or PPARg LBD fusion construct. For PPARa or
PPARg gene suppression, speciﬁc small interfering (si)RNA (Bioneer, Daejeon,
Korea) was transfected into cells with a MicroPorator (Digital Bio, Seoul,
Korea). After electroporation, cells were maintained overnight in growth
medium without antibiotics.
Docking simulation. Computer-aided docking simulation was conducted with
theDiscoveryStudio1.7program(Accelrys,Inc.,SanDiego,CA).TheLigandFit
module implemented in the receptor-ligand interaction protocol was used for
detailed calculation. We used the crystal structure of the ligand-bound human
PPARa and PPARg LBD (PDB ID: 3FEI and 3FEJ, respectively) (25). The
potential of mean force (26) was used as a scoring function to compare the
binding afﬁnity of the each molecule (Supplementary Table 1).
Quantitative RT-PCR analysis. Total RNA was isolated from cells or tissues
and cDNA was synthesized. For quantitive (q)RT-PCR reactions, the ampliﬁ-
cation was performed for 40 repetitive thermal cycles (94°C for 20 s, 60°C for
20 s, and 72°C for 20 s) with SYBR green (Invitrogen, Carlsbad, CA) in a My-IQ
thermocycler (Bio-Rad, Hercules, CA). The primers were designed and
synthesized from Bioneer (Daejeon, Korea). The primer sequences are listed
in Supplementary Table 2.
Metabolic assays. Fatty acid oxidation assays were performed as described
previously (23). Brieﬂy, cells were incubated in a-minimum essential medium
(Hyclone) containing 0.1 mmol/L palmitate (9,10-[
3H]palmitate, 5 mCi/mL;
PerkinElmer Life, Boston, MA) and 1% bovine serum albumin for 24 h. After
incubation, medium was precipitated with an equal volume of 10% trichloro-
acetic acid (Sigma), vigorously mixed, and centrifuged at 4°C for 10 min. The
supernatants were transferred to capless 1.5-mL microcentrifuge tubes, placed
in a scintillation vial containing 0.5 mL of water and incubated overnight at
55°C. Then tubes were removed and
3H2O contents were measured in a scin-
tillation counter.
Animal experiments. All animal experiments were approved by the Seoul
National University Animal Experiment Ethics Committee. Ten-week-old
C57BLKS/J-Lepr
db/Lepr
db or 7-week-old C57BL/6J male mice were purchased
from Central Laboratory Animal Inc. (Seoul, Korea). C57BLKS/J-Lepr
db/Lepr
db
mice were orally injected with vehicle (distilled water), WY14643, rosiglita-
zone, or CG301269 at the concentration of 50 mg/kg once a day for 1 month.
PPAR ligands were dissolved into distilled water. Animal experiments were
conducted twice. For myocardial ischemia/reperfusion experiments, C57BL/
6J mice underwent surgically-induced myocardial infarction and were orally
administered with various treatments, as described previously. Detailed ex-
perimental procedures are described in the Fig. 8 legend.
For the oral glucose tolerance test (OGTT) and intraperitoneal insulin
tolerance test (IPITT), mice were fasted for 24 h (for OGTT) or 6 h (for IPITT)
and were injected with glucose (5 g/kg, for OGTT; Sigma) or human insulin
(1 unit/kg, for IPITT; Lilly, Indianapolis, IN). The blood glucose level
was measured at indicated time point with Freestyle blood glucose meter
(Therasense, Uppsala, Sweden).
Biochemical analysis. Blood samples and liver lysates were collected from
each group of mice. Plasma and liver TG, FFA, and total cholesterol were
measured using Inﬁnity reagents (Thermo, Melbourne, Australia). Plasma
concentrations of LDL and HDL were determined as previously described (27).
Plasma insulin level was assessed with an insulin ELISA kit (Mercodia,
Uppsala, Sweden). Hepatotoxicity was measured by plasma alanine amino-
transferase (ALT) and aspartate aminotransferase (AST) levels.
Tissue section and staining. Frozen tissue dissects were prepared as de-
scribed previously (28). After mounting on glass slides and ﬁxation, dissected
samples were stained with Oil-red O solution and photographed at original
magniﬁcation 3100.
Myocardial ischemia/reperfusion surgery. C57BL/6J mice were anes-
thetized. Reperfused myocardial infarction surgery was performed as pre-
viously described (29). Brieﬂy, after anesthesia, mice were orally intubated
and connected to a murine ventilator (Harvard Apparatus, Holliston, MA). A
median sternotomy was performed, and the left anterior descending coronary
artery was ligated, occluded for 30 min, and then reperfused for 1 h. After
reperfusion, the chest wound was reapproximated and mice were extubated
and allowed to recover with supplemental oxygen until mobile.
Statistical analysis. Results were representative data from at least three
independent experiments. Mean data are presented with standard deviations
and shown as error bars in the graphs. P values were calculated from ANOVA
(Student-Newman-Keuls comparison test as post hoc). P , 0.05 was inter-
preted as being statistically signiﬁcant.
RESULTS
CG301269 increases transcriptional activities of
PPARa and PPARg. For the speciﬁc interactions be-
tween nuclear hormone receptors and their ligands, one of
the key chemical bonds is the hydrogen bond, which often
links between ligands and amino acid residues in the
ligand-binding domain of nuclear hormone receptors. To
develop a novel PPARa/g dual agonist, we used the
HipHop process (Catalyst software, Accelrys, Inc.) (30),
which provides potential accommodation statuses of
ligands and receptors to predict hypothetic three-
dimensional interactions based on the structures. Accord-
ing to the HipHop process, thiazolidine-4-carboxylic acid
and 5-methyl-2-phenyl-oxazole were linked with a phenoxy
to provide numerous hydrophobic interactions in the bind-
ing pocket.
A number of modiﬁed compounds were synthesized and
evaluated by transactivation reporter assays with both
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was selected for further evaluation. As shown in Fig. 1B
and C, CG301269 enhanced both PPARa-and PPARg-
dependent reporter activities in HEK 293 cells to an extent
comparable with those of the known agonists WY14643
and rosiglitazone, respectively. CG301269 stimulated the
transcriptional activities of murine and human PPARa
in a dose-dependent manner (Supplementary Fig. 1A and
B) but failed to activate other nuclear hormone recep-
tors, including PPARd and LXRa (Supplementary Fig. 1C
and D).
In mammalian one-hybrid assays, CG301269 activated
PPARa and PPARg with half-maximal effective concen-
tration (EC50) of 39 nmol/L and 2.69 mmol/L, respectively
(Supplementary Fig. 1E and F). Under the same condition,
EC50s for WY14643 (for murine PPARa) and rosiglitazone
(for murine PPARg) were 81 nmol/L and 14 nmol/L, re-
spectively. On the other hand, CG301269 transactivated
human PPARa and PPARg with a EC50 of 29 nmol/L and
5.3 mmol/L, respectively. These data suggest that CG301269
would be a potent PPARa activator but would be a rela-
tively weak PPARg activator.
CG301269 interacts with the LBD of PPARa and
PPARg. To further address whether CG301269 is able to
interact with the LBD of PPARa and PPARg, CG301269
was subjected to the docking study by comparison with
previously reported ternary structures of human PPARa
LBD (PDB ID: 3FEI) and human PPARg LBD (PDB ID:
3FEJ; Fig. 1D and E) (25). Similar to co-crystal structures
of human PPARa and PPARg with known PPARa/g dual
agonist (31,32), the electrostatic potential surface (mo-
lecular volume = 337.5 Å
3) and the docking score of
CG301269 toward PPARa/g implied that CG301269 might
ﬁt at the LBD of PPARa and PPARg with proper binding
mode (Supplementary Fig. 2 and Supplementary Table 1).
In addition, CG301269 altered trypsin digestion patterns,
probably due to changing conformation of liganded
PPARa and PPARg (Supplementary Fig. 3). These data
suggest that CG301269 would interact with PPARa and
PPARg through their LBD domains.
CG301269 promotes fatty acid oxidation. Because
CG301269 appeared to be a more potent agonist toward
PPARa than PPARg, the effect of CG301269 on fatty acid
oxidation was tested. In FAO murine hepatoma cells, vari-
ous PPARa target genes involved in b-oxidation were in-
duced by CG301269 in a dose-dependent manner (Fig. 2A).
CG301269-induced genes were acyl-CoA oxidase (ACO),
carnitine-palmitoyl transferase (CPT), fatty acid transporter
protein (FATP), and middle-chain acyl-CoA dehydrogenase
FIG. 1. CG301269 selectively activates PPARa and PPARg in vitro.
A: Chemical structure of CG301269. HEK293 cells were transiently
cotransfected with murine PPARa (B)o rPPARg (C) expression vec-
tor, RXRa expression vector, and DR1-luciferase reporter construct
and treated for 24 h with 1 mmol/L WY14643 (WY), rosiglitazone (Rosi),
GW501516 (GW), or CG301269 (CG269). Harvested cells were ana-
lyzed by reporter assay as described in RESEARCH DESIGN AND METHODS.
Each bar represents mean 6 SD of duplicates. *P < 0.05 vs. negative
control; #P < 0.01 vs. negative control. D and E: Docking modes of
CG301269 toward the LBD of human PPARa or g. D: PPARa-LBD (PDB
ID: 3FEI, binding site volume = 329.5 Å
3). E: PPARg-LBD (PDB ID:
3FEJ, binding site volume = 362.4 Å
3). Displayed amino acids are all
protein residues with a ligand contact distance £4.5 Å. The docking
protocol is described in RESEARCH DESIGN AND METHODS. CG301269 (stick
model) has similar binding sites and binding volume compared with
known PPARa/g dual agonist (red cloud); in particular, typical four
hydrogen bonds between the carboxylate of CG301269 and the Ser, His,
and Tyr residues of PPARa/g within hydrogen bond distance £3Å .
CG301269 can be accommodated at the hydrophobic pockets composed
of Met, Cys, and Gly residues of PPARa/g. Blue cloud, human PPARa;
yellow cloud, human PPARg; red cloud, binding site volume of recently
uploaded PPARa/g dual agonist.
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498 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.orgFIG. 2. CG301269 enhances in vitro fatty acid oxidation. FAO rat hepatoma cells (A), C2C12 myotubes (B), and 3T3-L1 adipocytes (C) were in-
cubated with indicated doses of WY, rosiglitazone (Rosi), or CG269 for 24 h. Relative gene expression was analyzed by use of qRT-PCR and
normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Each bar represents mean 6 SD of duplicates. □,( –); ,W Y( 1mmol/L);▨,
Rosi (1 mmol/L); , CG269 (0.5 mmol/L);▥, CG269 (1 mmol/L); ■, CG269 (5 mmol/L). *P < 0.05 vs. (–); #P < 0.01 vs. (–). D: FAO cells were
transfected with GFP siRNA (□)o rPPARa siRNA (■) and treated with indicated PPAR agonists (1 mmol/L) for 24 h. Relative gene expression was
measured by qRT-PCR and normalized by GAPDH. Each bar represents mean 6 SD of triplicates. *P < 0.05 vs. GFP siRNA (–); #P < 0.01 vs. GFP
siRNA (–); ¶P < 0.05 vs. GFP siRNA + WY or CG269. FAO (E), C2C12 (F), and 3T3-L1 (G) cells were incubated with 10 mmol/L of WY, Rosi, or
CG269 for 24 h. Fatty acid oxidation assay was performed as described in RESEARCH DESIGN AND METHODS. Each bar represents mean 6 SD of tripli-
cates. *P < 0.05 vs. negative control; #P < 0.01 vs. negative control. H: FAO cells were transfected with GFP siRNA (□)o rPPARa siRNA (■) and
were subjected to fatty acid oxidation assay. Each bar represents mean 6 SD of triplicates. *P < 0.05 vs. GFP siRNA; #P < 0.01 vs. GFP siRNA;
¶P < 0.05 vs. GFP siRNA + WY or CG269.
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3T3-L1 (Fig. 2C), and 3T3-F442A cells (Supplementary
Fig. 4A). However, knockdown of PPARa (Fig. 2D)w i t h
siRNA, but not PPARd (data not shown), attenuated the
induction of these fatty acid oxidation genes upon
CG301269, supporting the idea that CG301269 would se-
lectively act as a PPARa agonist.
Fatty acid oxidation assays were performed to further
examine whether CG301269 would indeed promote
b-oxidation. In various cell lines, CG301269 and WY14643
signiﬁcantly elevated fatty acid oxidation (Fig. 2E–G and
Supplementary Fig. 4B), which was required for activated
PPARa (Fig. 2H). Taken together, these ﬁndings indicate
that CG301269 would enhance lipid catabolism by induction
of fatty acid oxidation genes by way of PPARa activation.
CG301269 suppresses proinﬂammatory gene expres-
sion in vitro. As a dual activator of PPARa and PPARg,
CG301269 stimulated the expression of PPARg target
genes including aP2, CD36, adiponectin (Acrp30), and li-
poprotein lipase (LPL) in fully differentiated adipocytes
(3T3-L1 and 3T3-F442A cells) and white adipose tissue
(Supplementary Fig. 5A–C). Moreover, the expression of
PPARg target genes by CG301269 was prevented by
knockdown of PPARg with siRNA (Supplementary Fig.
5D). In differentiated 3T3-L1 adipocytes, certain genes
regulated by CG301269 were also modulated by rosiglita-
zone, implying that CG301269 appears to alter the ex-
pression of certain sets of genes by partial activation of
PPARg (Supplementary Fig. 6).
The fact that activation of PPARs with their ligands
drastically downregulates proinﬂammatory responses
(33–35) led us to investigate whether CG301269 would
repress proinﬂammatory gene expression. In RAW 264.7
macrophages and 3T3-L1 adipocytes, LPS and TNFa, re-
spectively, greatly stimulated the expression of proin-
ﬂammatory genes, including TNFa, interleukin-1b (IL-1b),
matrix metalloprotease 9 (MMP9), inducible nitric oxide
synthase (iNOS), monocyte chemoattractant protein-1
(MCP-1), chemokine (C-C motif ) receptor 2 (CCR2),
cyclooxygenase-2 (COX2), and IL-6 (Fig. 3). Notably, pre-
incubation with CG301269 suppressed LPS- and TNFa-
induced inﬂammatory responses in a dose-dependent
manner (Fig. 3). Similar results were obtained in TNFa-
induced 3T3-F442A adipocytes (Supplementary Fig. 7).
The inhibitory effect of CG301269 on proinﬂammatory
gene expression was comparable or even better than
known PPARa and PPARg ligands, WY14643, and rosigli-
tazone (Fig. 3 and Supplementary Fig. 7). These data
suggest that CG301269 would decrease proinﬂammatory
responses through activation of PPARa or PPARg.
FIG. 3. CG301269 suppresses proinﬂammatory gene expression in vitro. RAW 264.7 macrophages (A) and 3T3-L1 adipocytes (B) were pre-
incubated with indicated agonists for 12 h and were treated with LPS (10 ng/mL; A) for 6 h and TNFa (1 ng/mL; B) for 3 h. Relative gene expression
was determined by qRT-PCR and normalized by glyceraldehyde-3-phosphate dehydrogenase. Each bar represents mean 6 SD of duplicates. □, (-);
▤, LPS 10 ng/mL (A) or TNFa 1 ng/mL (B); ,W Y1mmol/L/LPS (A)o rW Y1mmol/L/TNFa (B);▨ Rosi 1 mmol/L/LPS (A) or Rosi 1 mmol/L/TNFa
(B);▥, CG269 1 mmol/L/LPS (A) or CG269 1 mmol/L/TNFa (B); ■, CG269 5 mmol/L/LPS (A) or CG269 5 mmol/L/TNFa (B). *P < 0.05 vs. negative
control; **P < 0.01 vs. negative control; #P < 0.05 vs. LPS (A) or TNFa (B); ¶P < 0.01 vs. LPS (A) or TNFa (B).
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plasma lipid and glucose proﬁles in db/db mice. To
explore the effects of CG301269 in vivo, we administered
CG301269 to obese and diabetic db/db mice. Unlike rosi-
glitazone, a strong PPARg ligand that yielded signiﬁcant
body weight gain as previously reported (11,36), CG301269
prevented body weight gain of db/db mice (Fig. 4A),
without food intake change (Supplementary Fig. 8). Acti-
vation of PPARa or PPARg with their ligands has been
reported to lower plasma glucose, insulin, and lipid con-
tents in diabetic individuals (9,10). Thus, we next exam-
ined whether CG301269 is able to achieve such beneﬁcial
effects on lipid and glucose metabolism. Consistent with
previous reports (10,12), WY14643 and rosiglitazone ef-
fectively improved hyperglycemia and lipid proﬁles in
db/db mice (Fig. 4B). As a PPARa/g dual agonist, CG301269
also remarkably diminished blood glucose, insulin, and lipid
contents (Fig. 4B). Additionally, CG301269 decreased
plasma LDL and increased plasma HDL levels (Fig. 4B),
implying that CG301269 appears to rescue cholesterol
metabolism in obese animals. Moreover, CG301269 de-
creased plasma ALT and AST levels by 25% in db/db mice
(Fig. 4B), indicating that CG301269 would not induce
hepatotoxicity, unlike pure PPARg agonists (37,38). Fur-
thermore, compared with known PPARa or PPARg
ligands, CG301269 did not increase liver weight or fat tis-
sue masses (Fig. 4C). These data strongly propose that
CG301269 would efﬁciently improve plasma glucose and
lipid contents without a signiﬁcant body weight gain (with
increased adiposity) or hepatotoxicity, or both.
CG301269 ameliorates glucose and insulin tolerance
in db/db mice. To assess whether CG301269 might affect
glucose and insulin tolerance in obese and diabetic ani-
mals, OGTT and IPITT assays were conducted in db/db
mice. Like WY14643 and rosiglitazone, CG301269 amelio-
rated glucose and insulin tolerance in obese db/db mice
(Fig. 5A and B). The effect of CG301269 on glucose and
insulin sensitivity was stronger than that of WY14643 and
weaker than that of rosiglitazone, which appeared to cor-
relate with the results that CG301269 is a strong PPARa
agonist but is a weak PPARg agonist.
In diabetic animals, expression of hepatic gluconeogenic
enzyme genes is greatly increased, contributing to hyper-
glycemia (39). Because we observed that CG301269
FIG. 4. CG301269 attenuates body weight gain in db/db mice. A: Body weight changes of PPAR agonists-administered obese and diabetic db/db
mice. Data (n = 6 for each group and n = 7 for CG269) were shown as symbols; ◇, vehicle (Veh); □, WY; △, Rosi; ○, CG269. Each bar represents
mean 6 SD. B: A series of plasma proﬁles from PPAR agonists-administered db/db mice. Data are means 6 SD. *P < 0.05 vs. Veh; #P < 0.01 vs. Veh;
§P < 0.001 vs. Veh. C: Average tissue weights of PPAR agonist-treated db/db mice. Each bar represents mean 6 SD. □, Veh; , WY;▨, Rosi; ■,
CG269. *P < 0.05 vs, Veh; #P < 0.01 vs, Veh. Gon, gonadal; Vis, visceral; Ret, retroperitoneal.
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db/db mice, the effect of CG301269 on gluconeogenic gene
expression was tested. As shown in Fig. 5C, CG301269
decreased the expression of key gluconeogenic genes,
such as phosphoenolpyruvate carboxykinase (PEPCK)
and glucose-6-phosphatase (G6Pase) in the liver of db/db
mice.
CG301269 improves hepatic steatosis in db/db mice.
Fatty liver is one common complication of obesity, insulin
resistance, and type 2 diabetes. Activation of PPARa has
been reported to alleviate fatty liver by increase of lipid
consumption and decrease of lipogenesis, whereas the
effect of activated PPARg on fatty liver is controversial
(40,41). Because CG301269 was developed and identiﬁed
as a PPARa/g dual agonist, we asked whether CG301269
might relieve hepatic steatosis in db/db mice. In accor-
dance with previous reports (40,41), rosiglitazone failed to
decrease hepatic steatosis, whereas WY14643 evidently
alleviated fatty liver (Fig. 6A and B). Similar to WY14643,
CG301269 greatly decreased hepatic TG, FFA, and cho-
lesterol accumulation in db/db mice (Fig. 6A). Reduced
hepatic lipid contents upon CG301269 were further moni-
tored through Oil-red O staining (Fig. 6B). As expected,
CG301269 increased the expression of fatty acid oxidation
genes in several metabolic tissues, including liver, skeletal
muscle, and white adipose tissue (Fig. 6C), but decreased
the expression of hepatic lipogenic genes (Supplementary
Fig. 9). CG301269 also elevated the plasma content of
adiponectin (Acrp30) (Fig. 4B), which enhances lipid me-
tabolism and alleviates metabolic disorders including fatty
liver (42). Although WY14643 induced hepatomegaly, a
pathologically enlarged liver induced by aberrant PPARa
activation and peroxisome proliferation, CG301269 did
not increase liver weight in db/db mice (Fig. 4C and Sup-
plementary Fig. 10). These results suggest that CG301269
would improve fatty liver without severe hepatomegaly,
a fatal side effect of potent PPARa activators.
CG301269 reduces fat cell size and proinﬂammatory
gene expression in db/db mice. Chronic and low-grade
inﬂammation in hypertrophic adipocytes containing large
amounts of lipid contents is reported to play a key role in
the progress of obesity-induced insulin resistance (43).
Because adipocyte size has been considered one of the
indicators of metabolic stresses, including insulin re-
sistance, inﬂammation, and hyperlipidemia, we measured
the fat cell size in CG301269-treated obese animals. In
white adipose tissue, CG301269 not only decreased fat cell
size but also downregulated the expression of in-
ﬂammatory genes, including TNFa, iNOS, and MCP-1, and
glucose-6-phosphate dehydrogenase (G6PD;F i g .7 A and B).
Furthermore, the expression levels of macrophage-speciﬁc
marker genes (i.e., CD68, F4/80, CD11b, and CD11c)w e r e
reduced by CG301269 in white adipose tissue of obese
db/db mice (Fig. 7C), implying that CG301269 may effec-
tively decrease hypertrophic adipocytes and repress proin-
ﬂammatory responses in obese animals.
CG301269 does not deteriorate heart failure. Previous
research indicated that PPARa/g dual agonists often
caused cardiovascular dysfunction (20,44,45). To test this
upon CG301269, we have conducted myocardial ischemia/
reperfusion surgical procedures with C57BL/6J mice and
db/db mice. Because of the low survival rate of db/db mice
after surgery, probably due to hyperglycemia (29), C57BL/6J
mice have been extensively analyzed. Compared with the
sham group, mice treated with vehicle or CG301269 re-
vealed the characteristics of heart failure, such as hypo-
kinetic wall motion abnormality in the septum, dilated left
ventricle (LV), altered LV function, and LV ﬁbrosis at
4 weeks after myocardial ischemia/reperfusion surgery
(Fig. 8A–C). More importantly, CG301269 treatment did
not further deteriorate these parameters, implying that
CG301269 may not aggravate heart failure. The body
weight, heart weight/body weight, and wet lung weight/
body weight were not changed by CG301269 administra-
tion (Supplementary Table 3). Together, these data pro-
posed that CG301269 might not exacerbate heart failure or
related cardiomyopathy, at least in C57BL/6J mice.
DISCUSSION
Type 2 diabetes and related complications are rising as
serious health problems in westernized societies. The
FIG. 5. CG301269 ameliorates glucose and insulin tolerance in db/db
mice. Mice were fasted and injected with glucose (A) or insulin (B)a s
described in RESEARCH DESIGN AND METHODS. Plasma glucose and insulin
levels were measured from the blood samples that were drawn at
baseline (t = 0 min) and indicated time points. ◇, vehicle; □, WY14643;
△, rosiglitazone; ○, CG301269. C: Relative gene expression of gluco-
neogenic genes from the liver of indicated drug-treated obese db/db
mice were determined by use of qRT-PCR and normalized with glycer-
aldehyde-3-phosphate dehydrogenase. Data represent means 6 SD. □,
Veh; , WY;▨, Rosi; ■, CG269. *P < 0.05 vs. Veh, #P < 0.01 vs. Veh.
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in metabolic disorders have prompted development of
PPARa/g dual activators in a single compound. In this
study, we identiﬁed CG301269 through virtual screening
for PPARa/g dual agonists and characterized its speciﬁcity
to activation of PPARa and PPARg. Compared with earlier
PPARa/g dual agonists, CG301269 seemed to exhibit fa-
vorable effects on obesity and hyperlipidemia, without the
concerns of weight gain, fatty liver, hepatotoxicity, tissue
hypertrophy, and ﬂuid retention.
CG301269 shows dual agonist activities for both PPARa
and PPARg, but shows higher afﬁnity to PPARa than
PPARg. Therefore, it seems likely that the mechanisms
responsible for CG301269-mediated regulation of lipid
homeostasis would be distinct from thiazolidinedione.
Even though CG301269 was able to enhance adipogenesis
as a partial PPARg agonist, the adipogenic effect of
CG301269 was much milder than that of rosiglitazone in
vitro with 3T3-L1 cells (data not shown). Rather, the
ﬁndings that CG301269 effectively stimulates PPARa ac-
tivities, even at a low dose, proposed the idea that
CG301269 would primarily govern lipid metabolism by
induction of fatty acid oxidation. Indeed, consistent with
in vitro experiments, CG301269 increased expression of
PPARa target genes in peripheral tissues of obese db/db
mice, suggesting that CG301269 would potently reduce extra
lipid contents by enhancing lipid catabolism, and thereby
result in the prevention of body weight gain, at least in part.
Fatty liver is a common complication in obesity and in
type 2 diabetes and is closely associated with insulin
FIG. 6. CG301269 improves hepatic steatosis in db/db mice. A: Accumulated lipids in liver of PPAR agonists-treated db/db mice. Liver TG, FFA, and
cholesterol levels were measured as described in RESEARCH DESIGN AND METHODS. Each bar represents mean 6 SD. □, Veh; , WY;▨, Rosi; ■, CG269.
*P < 0.05 vs. Veh. B: Oil-red O staining of liver tissue from PPAR agonist-treated db/db mice. Scale bar = 50 mm. C: Relative gene expression of each
gene in liver, skeletal muscle, and white adipose tissue (WAT) from db/db mice was determined by use of qRT-PCR and normalized by glyceral-
dehyde-3-phosphate dehydrogenase. Each bar represents mean 6 SD. □, Veh; , WY;▨, Rosi; ■, CG269. *P < 0.05 vs. Veh; #P < 0.01 vs. Veh.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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decreasing hepatic TG and FFA contents in obese db/db
mice, an effect probably due to higher efﬁcacy of CG301269
toward PPARa over PPARg. Intriguingly, CG301269-treated
obese db/db mice did not show hepatomegaly, a common
side effect of potent PPARa agonists in rodents (5,47). The
beneﬁcial effect against fatty liver without hepatomegaly is
not exclusive to CG301269, because several PPARa/g dual
agonists are reported to do so (18,48), However, its exact
molecular mechanism remains to be elucidated.
Low-grade and chronic inﬂammation is closely associ-
ated with metabolic disorders, including obesity, insulin
resistance, type 2 diabetes, and atherosclerosis. Enlarged,
hypertrophic fat cells secrete a number of proinﬂamma-
tory cytokines (43), and blockade of proinﬂammatory
responses ameliorates insulin resistance (49,50). In obese
and diabetic db/db mice, CG301269 reduced fat cell size
and repressed the expression of proinﬂammatory genes,
implying that CG301269 might contribute to anti-
inﬂammatory responses in the adipose tissue of obese
individuals. Although it is yet unclear whether reduced
expression of proinﬂammatory genes is a cause or effect
of CG301269 in obese animals, it is likely that the effects
of antiadiposity and the anti-inﬂammatory property of
CG301269 would contribute to improve insulin sensitivity.
We found it interesting that CG301269 potently pre-
vented the increase of body fat mass. Because many type 2
diabetic patients have associated overweight or obesity,
induction of extra fat accumulation could be a serious side
effect. Unfortunately, most of the PPARa/g dual agonists
developed to date have failed to solve this problem be-
cause they have preferential afﬁnity to PPARg (17,19).
Unlike previously synthesized PPARa/g dual agonists,
CG301269 partially activates PPARg. Compared with other
known PPARa/g dual agonists, the ﬁnding that CG301269
did not induce body weight gain proposes therapeutic
advantages of CG301269. Detailed molecular mechanism
(s) by which CG301269 would protect increase in adiposity
still remains to be elucidated.
We examined the effects of CG301269 on cardiac com-
plications because previously developed PPARa/g dual
agonists often deteriorate cardiovascular complications
(20,44,45). Although our experimental approaches were
not perfect to exclude the possibility that CG301269 is safe
for cardiovascular diseases, we observed that adminis-
tration of CG301269 into myocardial ischemia-induced
C57BL/6J mice for 4 weeks did not deteriorate heart failure
(Fig. 8 and Supplementary Table 3).
In summary, we have demonstrated that CG301269 has
beneﬁcial effects on glucose and lipid metabolism to re-
lieve metabolic disorders by selectively activating PPARa
and PPARg without several adverse effects, including body
weight gain, fatty liver, hepatotoxicity, and hepatomegaly,
which have been observed in previously identiﬁed PPAR
agonists, including PPARa/g dual agonists (36,37). CG301269
ameliorates lipid dysregulation by consumption of excess
lipids in peripheral tissues rather than redistribution of
them into adipose tissue to alleviate fatty liver and chronic
FIG. 7. CG301269 reduces average fat cell size and improves inﬂammation in WAT of db/db mice. A: WAT histology of CG301269-treated db/db
mice. WAT of each group of db/db mice was frozen-sectioned as described in RESEARCH DESIGN AND METHODS. Scale bar = 100 mm. The mRNA expression
of proinﬂammatory genes (B) and macrophage marker genes (C) in WAT of PPAR agonists-treated db/db mice was determined by use of qRT-PCR
and normalized by glyceraldehyde-3-phosphate dehydrogenase. Data represent mean 6 SD. □, Veh; , WY;▨, Rosi; ■, CG269. *P < 0.05 vs. Veh;
#P < 0.01 vs. Veh. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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be a potential lead compound against obesity and insulin
resistance.
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